ReviewAnnals of hematology2020
Modern management of splenomegaly in patients with myelofibrosis.
Review in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Spleen-derived circulating intercellular adhesion molecule 2 promotes osteosclerosis in chronic myelofibrosis.Bone research · 2026Article
- Splenic radiotherapy before allogeneic transplantation for myelofibrosis.British journal of haematology · 2026Article
- A model to estimate spleen volume from palpated spleen length in patients with myelofibrosis.Annals of hematology · 2026Article
- Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.Frontiers in oncology · 2026Review
- Extramedullary Hematopoiesis in the Cerebral Dura Resulting in Fatal Brain Herniation in a Patient With Secondary Myelofibrosis: A Case Report.Case reports in hematology · 2026Article
- The role of splenic irradiation prior to allogeneic hematopoietic stem transplantation in myelofibrosis: a review of the literature.Bone marrow transplantation · 2025Review
- Quantitative assessment of innate myeloid cells in myelofibrosis: insights into myeloid and plasmacytoid dendritic cell depletion and disease progression.Annals of hematology · 2025Article
- Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.Journal of hematology · 2025Article
- Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.American journal of hematology · 2025Review
- Model-Assisted Spleen Contouring for Assessing Splenomegaly in Myelofibrosis: A Fast and Reproducible Approach to Evaluate Progression and Treatment Response.Journal of clinical medicine · 2025Article
- Application of IVIM in the assessment of the spleen in patients with myelofibrosis.Frontiers in oncology · 2025Article
- Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2025Review
- Unusual renal displacement due to massive splenomegaly: a rare case report and review of literature.The Journal of international medical research · 2024Review
- Applying enhanced recovery after surgery protocols in a patient with a giant spleen: a case report.Frontiers in oncology · 2024Article
- Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.EJHaem · 2023Review
- Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.Internal medicine (Tokyo, Japan) · 2022Article
- Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.American journal of hematology · 2022Review
- The gut microbiome contributes to splenomegaly and tissue inflammation in a murine model of primary biliary cholangitis.Annals of translational medicine · 2022Article
- Radiotherapy for symptom palliation of splenomegaly in patients with haematological malignancies.Molecular and clinical oncology · 2021Article
- Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm which can lead to massive splenomegaly secondary to extramedullary hematopoiesis. Patients frequently exhibit debilitating symptoms including pain and early satiety, in addition to cellular sequestration causing severe cytopenias. JAK 1/2 inhibitors, such as ruxolitinib and fedratinib, are the mainstay of therapy and produce significant and durable reductions in spleen volume. However, many patients are not eligible for JAK 2 inhibitor therapy or become refractory to treatment over time. Novel therapies are in development that can reduce the degree of splenomegaly for some of these patients. However, splenectomy, splenic irradiation, and partial splenic artery embolization remain valuable therapeutic options in select patients. In this review, we will discuss currently available pharmacologic therapies and describe promising drugs currently in development. We will also delve into the efficacy and safety concerns of splenectomy, splenic irradiation, and partial splenic artery embolization. Finally, we will propose a treatment algorithm to help guide clinicians in the management of symptomatic splenomegaly in patients with MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.